Back to News & Events

CFB Announces Annual Applied Research and Development Awards

Awards support innovative research collaborations between academic faculty and regional bioscience companies.

The Center for Biotechnology at Stony Brook University has announced the recipients of the 2019-2020 Applied Research & Development (ARaD) awards. The ARaD Program is designed to help bridge the gap between the early-stage technology discovery and development capabilities of the academic community, and the later-stage commercial development interests of the bioscience industry.

The program currently provides matching funds on a competitive basis to support collaborations between Stony Brook University faculty and New York State corporate partners in all areas of medical biotechnology. The primary interest is in supporting development of technologies that will help companies hit commercially relevant milestones, and that have the potential to positively impact the New York State economy.

Projects supported this year include the further development of an Intensive Care Unit temporary pacemaker, a novel material platform to improve extracorporeal membrane oxygenation (ECMOs) in heart-lung machines, further development of skin brightening agents, and a novel therapeutic to treat Lung Cancer.

“Through our participation in the Applied Research and Development Program at the Center for Biotechnology, we have been able to access the expertise of Dr. Wei Lin in the Department of Biomedical Engineering to collaborate on strategic research projects” stated Linda Towler, CEO of Avery Biomedical Devices, a global leader in high reliability diaphragm pacemakers. “This research and development collaboration has allowed us to considerably accelerate our product development and we expect it to generate significant new revenue for the company downstream.”

“The Center for Biotechnology is thrilled to be able to continue to collaborate with New York State companies to help them develop commercially promising technologies that will lead to strategic partnerships, investment, corporate revenues, and job creation” said Diane Fabel, Director of Operations for the Center for Biotechnology. “The projects supported by this year’s Applied Research and Development awards exemplify the innovative science happening all around us both in our academic institutions and bioscience companies. The Center for Biotechnology is excited to be an engine promoting interactions between the two to help fuel the overall bioscience ecosystem in the region.”

The ARaD Program is part of a suite of programs and services provided by the Center for Biotechnology (CFB) focused on accelerating the development of biomedical technologies in order to have a positive impact on human health and society.

2019-2020 Applied Research and Development Awards

“Temporary Pacemaker” Avery Biomedical Devices & Dr. Wei Lin, Associate Professor, Biomedical Engineering, Stony Brook University

“c-VACNT material bio-interaction studies” CVD Equipment Corporation & Dr. Srinivas Pentyala, Professor and Director of Translational Research, Anesthesiology, Stony Brook Medical Center

“Evaluation of Hydrogenated Curcumins as Skin Brightening Agents with Novel Antimelanogenic and Antioxidant” BioCogent, LLC & Dr. Sandford Simon, Professor, Biochemistrty & Cell Biology and Pathology, Stony Brook University

“Evaluation of small molecule Bax activators in mouse models of lung cancer” PHD Biosciences & Dr. Thomas Zimmerman, Assistant Professor, Director, Division of Laboratory Animal Resources, Stony Brook University; Attending Veterinarian, Brookhaven National Laboratory; Attending Veterinarian, Cold Spring Harbor Laboratory.

Click here for PDF version of announcement. 

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => all
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 5031
                    [post_author] => 3
                    [post_date] => 2026-08-10 12:17:19
                    [post_date_gmt] => 2026-08-10 16:17:19
                    [post_content] => 

Attention Stony Brook University Faculy and Staff: Applications for the second cycle of the President’s Fast Impact Fund (FIF) opened August 3, 2026. Open to all Stony Brook faculty and staff, this special initiative supports immediate-impact projects that can be launched quickly and deliver results within six to ten months.

The FIF provides awards of up to $300,000 focused on low‑investment, high‑reward initiatives that create visible, positive change. Examples of projects that would be considered include specialized equipment or technology acquisitions, pilot programs or proof‑of‑concept initiatives, targeted renovations or seed funding, among other opportunities.

All proposals must include a customized, high-level budget and be endorsed by the relevant vice president or dean with authority to implement the project. Applications for the August cycle will be available beginning August 3 with submissions due Friday, August 21 by 5 pm, ET. Please visit the Fast Impact Fund website for additional information and to submit an application.

[post_title] => SBU President’s Fast Impact Fund (FIF) [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => sbu-presidents-fast-impact-fund-fif [to_ping] => [pinged] => [post_modified] => 2026-08-19 08:30:44 [post_modified_gmt] => 2026-08-19 12:30:44 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=5031 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 4051 [post_author] => 4 [post_date] => 2023-03-16 14:01:07 [post_date_gmt] => 2023-03-16 14:01:07 [post_content] =>

The NIH is providing an opportunity for grantees to participate in an online entrepreneurial education platform aimed at teaching academic innovators methods to assess the commercial value of their biomedical technologies through our commercialization assistance program, Concept to Clinic: Commercializing Innovation Education (e-C3i). This program provides entrepreneurial education for investigators who are interested in better understanding the value of their innovation in addressing an unmet market need. The eC3i course is being offered to investigators with active (or in a No-Cost Extension through 9/23) NIH-funded research projects from participating Institutes and Centers.

All applications must be received no later than April 14th, 2023. Apply Today! Applications can be submitted to NIBIB-SBIR@mail.nih.gov. All NHLBI grantees are encouraged to contact us (nhlbi_sbir@mail.nih.gov) if you are interested in participating or have any questions about the application process. Learn more here.

[post_title] => NIH Grantees: Learn How to Commercialize Your Tech [post_excerpt] => The NIH is providing an opportunity for grantees to participate in an online entrepreneurial education platform aimed at teaching academic innovators methods to assess the commercial value of their biomedical technologies. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => nih-ec3i-2023 [to_ping] => [pinged] => [post_modified] => 2024-08-22 11:34:34 [post_modified_gmt] => 2024-08-22 15:34:34 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4051 [menu_order] => 5 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 2436 [post_author] => 4 [post_date] => 2016-10-24 13:50:10 [post_date_gmt] => 2016-10-24 13:50:10 [post_content] => The Life Sciences Summit is an early stage investor and business development conference that highlights innovation. On November 2-3, 2016, emerging biotech companies and academic innovators will convene in New York City to connect with investors and strategic partners with the goal of moving new discoveries through clinical development. The two-day program features corporate presentations by promising young companies with transformative science that targets unmet medical needs. It also features informative plenary sessions, business workshops, and therapeutic sessions. There is still time to register and participate in this innovative conference that provides attendee the opportunity to networking with potential investors and strategic partners. REGISTER TODAY!   [post_title] => Life Sciences Summit 2016: November 2-3, NYC [post_excerpt] => Don't Miss the Life Sciences Summit 2016! Organized by the Center for Biotechnology and Demy-Colton, the Summit is an early stage investor and business development conference that highlights innovation. The objective of the event is to connect emerging biotech companies and academic innovators with the capital and strategic partners they will need to move new discoveries through clinical development. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => life-sciences-summit-2016-november-2-3-nyc [to_ping] => [pinged] => [post_modified] => 2016-12-22 17:28:08 [post_modified_gmt] => 2016-12-22 17:28:08 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2436 [menu_order] => 163 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 4445 [post_author] => 4 [post_date] => 2024-06-10 15:37:44 [post_date_gmt] => 2024-06-10 19:37:44 [post_content] =>

Envisagenics, an AI-enabled biotechnology firm specializing in RNA splicing therapeutics, has announced the completion of its Series B funding round. This round included investments from existing supporters Third Kind Venture Capital, Empire State Development, and Red Cell Partners, as well as new strategic investor Bristol Myers Squibb, which has been collaborating with Envisagenics on oncology research since 2022.

Read more about Envisagenics Series B award here.

[post_title] => CFB Client Envisagenics Secures $25 Million Series B Funding to Advance RNA Splicing Therapeutics [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => envisagenics-secures-25-million-series-b-funding-to-advance-rna-splicing-therapeutics [to_ping] => [pinged] => [post_modified] => 2025-05-01 12:39:53 [post_modified_gmt] => 2025-05-01 16:39:53 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4445 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 4 [current_post] => -1 [before_loop] => 1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 5031 [post_author] => 3 [post_date] => 2026-08-10 12:17:19 [post_date_gmt] => 2026-08-10 16:17:19 [post_content] =>

Attention Stony Brook University Faculy and Staff: Applications for the second cycle of the President’s Fast Impact Fund (FIF) opened August 3, 2026. Open to all Stony Brook faculty and staff, this special initiative supports immediate-impact projects that can be launched quickly and deliver results within six to ten months.

The FIF provides awards of up to $300,000 focused on low‑investment, high‑reward initiatives that create visible, positive change. Examples of projects that would be considered include specialized equipment or technology acquisitions, pilot programs or proof‑of‑concept initiatives, targeted renovations or seed funding, among other opportunities.

All proposals must include a customized, high-level budget and be endorsed by the relevant vice president or dean with authority to implement the project. Applications for the August cycle will be available beginning August 3 with submissions due Friday, August 21 by 5 pm, ET. Please visit the Fast Impact Fund website for additional information and to submit an application.

[post_title] => SBU President’s Fast Impact Fund (FIF) [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => sbu-presidents-fast-impact-fund-fif [to_ping] => [pinged] => [post_modified] => 2026-08-19 08:30:44 [post_modified_gmt] => 2026-08-19 12:30:44 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=5031 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 284 [max_num_pages] => 95 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) [query_cache_key:WP_Query:private] => )

SBU President’s Fast Impact Fund (FIF)

More Information

NIH Grantees: Learn How to Commercialize Your Tech

More Information

Life Sciences Summit 2016: November 2-3, NYC

More Information

CFB Client Envisagenics Secures $25 Million Series B Funding to Advance RNA Splicing Therapeutics

More Information